Net margin is calculated as Net Income divided by its Revenue. Medicure's Net Income for the
three
months ended in Mar. 2026 was €-0.26 Mil. Medicure's Revenue for the
three
months ended in Mar. 2026 was €5.01 Mil. Therefore, Medicure's net margin for the quarter that ended in Mar. 2026 was -5.11%.
The historical rank and industry rank for Medicure's Net Margin % or its related term are showing as below:
STU:NGQ1'
s Net Margin % Range Over the Past 10 Years
Min: -98.08 Med: -3.8 Max: 160.03
Current: -21.74
STU:NGQ1's Net Margin % is ranked worse than 81.92% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs STU:NGQ1: -21.74
Medicure (STU:NGQ1) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Medicure Net Margin % Related Terms
Medicure Net Margin % Historical Data
* Premium members only.
The historical data trend for Medicure's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicure Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicure's Net Margin % distribution charts can be found below:
* The bar in red indicates where Medicure's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicure (STU:NGQ1) has a Net Margin % of -5.11% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Medicure and its competitors. According to the industry distribution chart, Medicure ranks #784 out of 957 companies in the Drug Manufacturers industry, placing it in the top 81.9%.
Is Medicure's Net Margin % too high?
Medicure's current Net Margin % is -5.11%. Based on the distribution chart, Medicure ranks #784 out of 957 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicure has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Medicure's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #784 out of 957 companies for Net Margin %. This places Medicure in the lower half of its industry. The industry median Net Margin % is 5.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Medicure and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicure's current Net Margin % is -5.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Medicure (STU:NGQ1) has a current Net Margin % of -5.11%. The stock's GF Value™ is €0.76, compared to a current price of €0.63 — trading 17.8% below its estimated fair value. The current Net Margin % is -5.11%. Medicure's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Medicure (STU:NGQ1), the current Net Margin % is -5.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicure (STU:NGQ1) Overvalued in 2026?
Based on GuruFocus' analysis, Medicure stock appears to be undervalued.
The current stock price of €0.63 is trading 17.8% below its estimated GF Value™ of €0.76.
Key valuation signals for STU:NGQ1:
Net Margin %: -5.11%
GF Value™: €0.76 vs. price of €0.63 (17.8% below fair value)
No single metric tells the full story. See the STU:NGQ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
57GF Score
Get the complete analysis for STU:NGQ1
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NGQ1 has been successfully added to your 
